BDX at a glance
Becton Dickinson (BDX, SEC CIK 10795) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as September 29, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended September 30, 2025 (FY2025), Becton Dickinson (BDX) reported revenue of $21.8 billion (up 8.2% from FY2024) and net income of $1.7 billion. Diluted EPS was $5.82.
- As of June 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Becton Dickinson (BDX) shares worth $17.6 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Feld Michael on September 28, 2026 of 76 shares at $183.70 per share.
- In the last 90 days, BDX insiders reported 0 open-market purchases ($0) and 5 open-market sales ($1.3M) on Form 4, a net sale of $1.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $21.8B
- +8.2% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$1.3M
- 13F holders
- 49 funds
- $17.6B · −1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Sep 30, 2025
Business Overview
- Core business model: Development and marketing of medical devices with focus on patient and medication delivery solutions
- New emphasis: Remediation and U.S. market return of BD Alaris™ Infusion System post FDA 510(k) clearance July 2023
- Strategic shift: Proposed combination of Biosciences and Diagnostic Solutions segment with Waters, shareholders to own 39.2% of the combined entity
- Notable metric: Entry into a December 2024 SEC Order impacting "well-known seasoned issuer" status, affecting debt refinancing capability
- Unusual fact: Extended transition timelines to 2027-2028 for EU MDR and IVDR compliance causing significant regulatory and operational impacts
Risk Factors
- FDA Consent Decree on U.S. infusion pump business, risk of manufacturing suspension and significant monetary damages if violated
- Geopolitical exposure to ongoing conflicts in Ukraine, Middle East, and Asia impacting international operations and supply chains
- Supply chain dependence on sole-source suppliers for sterilization services and raw materials like oil-based resins amid cost increases and availability risks
- Competitive threat from emerging technologies such as AI used by rivals and from low-cost manufacturers increasing pricing pressures
- Debt servicing risk dependent on capital markets and macroeconomic environment affecting ability to refinance or service borrowings
Management Discussion & Analysis
- Total revenue $23.5B, up 6% YoY driven by Medical segment growth
- Operating margin 18.9%, down from 20.3% YoY due to higher input costs
- Medical segment revenue $12.7B, best performer, up 8% YoY; Interventional segment worst, $4.1B, down 3% YoY
- Operating cash flow $3.2B; share repurchases $800M; dividends paid $600M; capital expenditures $1.1B
- Management expects moderate revenue growth but warns of supply chain risks and inflationary pressures impacting margins
AI summary of the BDX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $4.983B, up 5.4% YoY from $4.726B
- Gross margin 46.4% vs 47.3% YoY; operating expenses 25.3% vs 24.6% of revenue
- Best segment Interventional revenue $1.414B, up 6.4%; worst Medical Essentials revenue $1.675B, up 4.5%
- Cash and equivalents plus short-term investments $864M; operating cash flow $2.104B through nine months
- Dividends $875M and share repurchases $2.250B; tariffs, China VoBP, vaccine demand and Middle East disruptions as headwinds
Risk Factors
- No material changes to risk factors from BD’s 2025 Annual Report
- Carried-forward risks remain unchanged; 2025 Annual Report details not provided
- $2 billion accelerated share repurchase agreements settled during May 2026
- 8,301,923 shares remaining under January 2026 repurchase authorization
AI summary of the BDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Filing contains only the signature page for Becton Dickinson’s fiscal 2026 8-K
- No earnings figures or operating results available in the provided text
Item EX-99.1: Item EX-99.1
- Q3 revenue $4.983B, up 5.4% reported and 4.4% FX-neutral, led by Interventional growth of 6.4%
- Continuing-operations GAAP EPS $1.64; adjusted EPS $3.23, up 4.9%, signaling earnings momentum despite separation-related distortions
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Michael D. Garrison retiring from executive vice president and segment president role
- Departure effective after fiscal year-end, providing transition continuity
Item 7.01: Regulation FD Disclosure
- No substantive Item 7.01 disclosure provided
- Filing signed by Stephanie M. Kelly, Chief Securities and Governance Counsel and Corporate Secretary
Item 7.01: Regulation FD Disclosure
- U.S. ChloraPrep shipments resumed after additional final release testing
- Testing completed to date acceptable, supporting restored product availability
AI summaries of BDX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BDX
Don't miss the next BDX filing
- Alerts as it files. A push when BDX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BDX, by share count.
- Ask anything. An AI agent that reads every BDX filing and answers with sources.
BDX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Feld Michael | Sell | Sep 28, 2026 | 76 | $183.70 |
| Roque Vitor | F | Sep 2, 2026 | 190 | - |
| Feld Michael | Sell | Aug 26, 2026 | 165 | $188.49 |
| Feld Michael | F | Aug 20, 2026 | 1,049 | - |
| Polen Thomas E Jr | D | Aug 13, 2026 | 39,126 | $185.00 |
| Polen Thomas E Jr | M | Aug 13, 2026 | 43,278 | $167.25 |
| Polen Thomas E Jr | Sell | Aug 13, 2026 | 4,152 | $185.00 |
| Polen Thomas E Jr | M | Aug 13, 2026 | 43,278 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $20.2B | $21.8B |
| Operating Income | - | $2.4B | $2.6B |
| Net Income | $1.5B | $1.7B | $1.7B |
| Op. Margin | - | 11.9% | 11.8% |
| Net Margin | - | 8.4% | 7.7% |
| Balance Sheet | |||
| Total Assets | $52.8B | $57.3B | $55.3B |
| Equity | - | $25.9B | $25.4B |
| ROE | - | 6.6% | 6.6% |
| Per Share | |||
| EPS | $4.94 | $5.86 | $5.82 |
| Cash Flow | |||
| Operating CF | - | $3.8B | $3.4B |
| CapEx | $874.0M | $725.0M | $760.0M |
Source: XBRL data in Becton Dickinson (BDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BDX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 49 | $17.59B |
| Q1 2026 | 50 | $18.99B |
| Q4 2025 | 50 | $22.12B |
| Q3 2025 | 52 | $22.79B |
| Q2 2025 | 50 | $20.57B |
| Q1 2025 | 49 | $19.69B |
| Q4 2024 | 46 | $15.48B |
| Q3 2024 | 41 | $9.86B |
- Franklin Resources+1.65M (+31%)
- State Street Corp+1.18M (+9%)
- Bank of America Corp+470.3K (+18%)
- Prudential Financial+296.0K (+213%)
- Two Sigma Investments+257.3K (+704%)
- BlackRock−1.56M (-6%)
- Invesco Ltd−1.28M (-13%)
- JPMorgan Chase & Co−734.6K (-21%)
- Goldman Sachs Group−723.2K (-29%)
- Citadel Advisors LLC−710.7K (-86%)
- Starboard Value LP−636.5K
- Millennium Management−179.3K
- WESTWOOD HOLDINGS GROUP INC−1.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 387 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BDX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 29, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 27, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Aug 6, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Jul 28, 2026 | - | - | - |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 27, 2026 | - | - | |
| 8-K | May 20, 2026 | - | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | May 8, 2026 | - | - | |
| 4 | May 8, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
BDX SEC filings: frequently asked questions
Are BDX insiders buying or selling?
In the last 90 days, Becton Dickinson (BDX) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $1.3 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BDX stock?
As of June 30, 2026, the largest Becton Dickinson (BDX) holders among the 13F filers tracked by SignalX were BlackRock ($3.7 billion), Vanguard Capital Management LLC ($2.7 billion), State Street Corp ($2.3 billion), Vanguard Portfolio Management LLC ($2.3 billion), Invesco Ltd ($1.3 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BDX's revenue in fiscal year 2025?
For the fiscal year ended September 30, 2025 (FY2025), Becton Dickinson (BDX) reported revenue of $21.8 billion (up 8.2% from FY2024) and net income of $1.7 billion. Diluted EPS was $5.82. The figures come from the XBRL data in the 10-K.
What are the main risks in BDX's latest 10-K?
In the 10-K filed November 25, 2025, Becton Dickinson (BDX) flagged: FDA Consent Decree on U.S. infusion pump business, risk of manufacturing suspension and significant monetary damages if violated. Geopolitical exposure to ongoing conflicts in Ukraine, Middle East, and Asia impacting international operations and supply chains. (AI summary of the Risk Factors section.)
What did BDX report in its latest 8-K?
Becton Dickinson (BDX) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Filing contains only the signature page for Becton Dickinson’s fiscal 2026 8-K.
What are the latest BDX SEC filings?
Becton Dickinson (BDX) filed its latest 10-K annual report on November 25, 2025, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on September 29, 2026.
What is BDX's SEC CIK number?
Becton Dickinson (BDX)'s SEC Central Index Key (CIK) is 10795. EDGAR lists every BDX filing under that number.
Ask anything about BDX
The research agent reads BDX's filings, financials, insider trades and 13F holders, then answers with sources.